SVA [SINOVAC BIOTECH] NT 20-F: (Original Filing)
[]
[Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today ]
[Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today ]
[Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction Under the terms of the Amalgamation Agreement, the Amalgamation Agreement may be terminated by the Company or Parent if the amalgamation of Amalgamation Sub with and into the Company (the “Amalgamation”) has not oc]
[Sinovac Resumes Production and Operation at Sinovac Beijing’s Quality Assurance Department The successful resumption of regular production and operations at Sinovac Beijing’s Shangdi manufacturing facility follows the events of April 17, 2018, when Aihua Pan, the Chairman of the Board of Sinovac Bei]
[Sinovac Resumes Production and Operation at Sinovac Beijing’s Quality Assurance Department The successful resumption of regular production and operations at Sinovac Beijing’s Shangdi manufacturing facility follows the events of April 17, 2018, when Aihua Pan, the Chairman of the Board of Sinovac Bei]
[Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Compan]
[Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary – - Reaffirms Commitment to Take All Appropriate Actions to Protect Compan]
[Sinovac Announces Preliminary Results of Phase III Trial on sIPV BEIJING, April 19, 2018 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactiva]